Current screening and treatments in retinopathy of prematurity in the US

Retinopathy of prematurity (ROP) is a complex disease characterized by an aberrant developmental retinal angiogenesis in preterm infants and can carry significant visual morbidity, including retinal detachment and blindness. Though large scale, randomized clinical trials have improved our understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Suelves, Ana M, Shulman, Julia P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398742/
https://www.ncbi.nlm.nih.gov/pubmed/28539800
http://dx.doi.org/10.2147/EB.S94439
_version_ 1783230521173606400
author Suelves, Ana M
Shulman, Julia P
author_facet Suelves, Ana M
Shulman, Julia P
author_sort Suelves, Ana M
collection PubMed
description Retinopathy of prematurity (ROP) is a complex disease characterized by an aberrant developmental retinal angiogenesis in preterm infants and can carry significant visual morbidity, including retinal detachment and blindness. Though large scale, randomized clinical trials have improved our understanding of the pathophysiology and progression of the disease, the management of ROP remains a challenge for ophthalmologists. This review addresses the up-to-date screening approach, diagnosis, and treatment guidelines for ROP in the US.
format Online
Article
Text
id pubmed-5398742
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53987422017-05-24 Current screening and treatments in retinopathy of prematurity in the US Suelves, Ana M Shulman, Julia P Eye Brain Review Retinopathy of prematurity (ROP) is a complex disease characterized by an aberrant developmental retinal angiogenesis in preterm infants and can carry significant visual morbidity, including retinal detachment and blindness. Though large scale, randomized clinical trials have improved our understanding of the pathophysiology and progression of the disease, the management of ROP remains a challenge for ophthalmologists. This review addresses the up-to-date screening approach, diagnosis, and treatment guidelines for ROP in the US. Dove Medical Press 2016-05-20 /pmc/articles/PMC5398742/ /pubmed/28539800 http://dx.doi.org/10.2147/EB.S94439 Text en © 2016 Suelves and Shulman. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Suelves, Ana M
Shulman, Julia P
Current screening and treatments in retinopathy of prematurity in the US
title Current screening and treatments in retinopathy of prematurity in the US
title_full Current screening and treatments in retinopathy of prematurity in the US
title_fullStr Current screening and treatments in retinopathy of prematurity in the US
title_full_unstemmed Current screening and treatments in retinopathy of prematurity in the US
title_short Current screening and treatments in retinopathy of prematurity in the US
title_sort current screening and treatments in retinopathy of prematurity in the us
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398742/
https://www.ncbi.nlm.nih.gov/pubmed/28539800
http://dx.doi.org/10.2147/EB.S94439
work_keys_str_mv AT suelvesanam currentscreeningandtreatmentsinretinopathyofprematurityintheus
AT shulmanjuliap currentscreeningandtreatmentsinretinopathyofprematurityintheus

Ejemplares similares